Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma Grant

The Pfizer competitive grant program for Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma aims to support research that provides insights into the safety and efficacy of elranatamab in real-world scenarios. This initiative encourages projects addressing various aspects such as outpatient administration, prior treatment impacts, infection management, and identifying refractoriness biomarkers. Grant applications are welcomed from eligible organizations that can demonstrate a commitment to improving patient outcomes in this critical area of medical need.

Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
This competitive grant program seeks to support research studies that focus on generating evidence on the use of elranatamab in multiple myeloma in the real world setting.
Project Types and Area of Interest
Projects that will be considered for Pfizer support will focus on:
Safety and efficacy of elranatamab in the context of real-world use.Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies.Impact of prior treatments (BsAb, CAR-T, ADC) on elranatamab outcomes, and wash-out period between treatments.Infection patterns, timing, types, and management strategies including Ig replacement therapy.Identifying clinical and biological features of refractoriness, early- or late-response, relapse to elranatamab and establishing response biomarkers.

Eligibility

The institution and Principal Investigator (PI) must be based in one of the eligible countries noted above.
Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
The PI must be an employee or contractor of the requesting organization.
Requesting organization must be legally able to receive award funding directly from Pfizer Inc. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application.

Ineligibility

Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Inc. may be subject to rescission.